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On September 27, 2007, President George W. Bush signed the Food and Drug
Administration Amendments Act of 2007 (FDAAA),' ushering in a new regime of
postmarket authority for the Food and Drug Administration (FDA). Among other
things, FDAAA authorized FDA to require labeling changes, postmarket studies,
and Risk Evaluation and Mitigation Strategies (REMS). 2 Under the last authority,
where certain criteria are met, FDA may require a drug manufacturer to propose a
REMS-which can range in scope from a simple medication guide to complex and
onerous "elements to assure safe use" (ETASU)-as part of a new drug application
(NDA), abbreviated new drug application (ANDA), or biologics license application
(BLA), or after a drug has been approved by FDA.3
Prior to FDAAA, certain drug and biologics manufacturers implemented
plans designed to mitigate risk (most recently known as "risk management plans"
or RiskMAPs).4 The critical difference, however, was that these were generally
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1. Pub. L. No. 110-85, 121 Stat. 823 (codified as amended in scattered sections of 21 U.S.C.); see
also U.S. Food & Drug Admin., Food and Drug Administration Acts (FDAAA) of 2007,
http://www.fda.gov/Regulatorylnformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/Signi
ficantAmendmentstotheFDCAct/FoodandDrugAdministrationAmendmentsActof2OO7/defaut.htm (last
visited May 17, 2010) (detailing the new regulatory Amendments signed into law by President Bush in
September 2007).
2. FDAAA § 901(a), 121 Stat. at 922-39 (codified at 21 U.S.C. §§ 355(o)-(p), 355-1(West Supp.
2009)).
3. See infra Partl I.A.
4. See generally U.S. FOOD & DRUG ADMIN., U.S. DEP'T OF HEALTH & HUMAN SERVS.,
GUIDANCE FOR INDUSTRY DEVELOPMENT AND USE OF RISK MINIMIZATION ACTION PLANS (2005)
(outlining FDA guidance to industry on the development, implementation, and evaluation of
RiskMAPs).
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voluntary agreements. In contrast, FDA's new REMS authority gives the agency
the power to impose mandatory plans, 6 and a manufacturer's failure to comply with
a requirement of an approved REMS may subject a responsible person to criminal
sanctions as well as significant civil monetary penalties.7 As a result, both FDA and
the companies that the agency regulates are operating in a new environment.
FDAAA gave FDA significant new authority and correspondingly expanded its
obligations. Similarly, regulated industry is facing a regulator that is increasingly
focused on monitoring products once they are in the marketplace. 9
Indeed, although authors have begun to chronicle FDA's use of its new
REMS authority,' 0 very little has been written to date about the practical impact the
REMS authority may have on drug manufacturers. This Article therefore addresses
some of the challenges and opportunities that manufacturers may face in the post-
REMS world, 1 including the impact that REMS may have on tort liability 2 and, in
5. Gerald F. Masoudi, Legal Developments in the Enforcement of Food and Drug Law, 63 FOOD
& DRUG L.J. 585, 586 (2008).
6. 21 U.S.C. § 355-1(a)(1)-(2). If the Secretary determines that a risk evaluation and mitigation
strategy is necessary, Section 355-1 provides that an applicant "shall submit to the Secretary as part of
such application a proposed risk evaluation and mitigation strategy." Id. § 355-1(a)(1) (emphasis added).
7. Pursuant to Section 505(p) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), a
responsible person or entity is prohibited from introducing or delivering for introduction into interstate
commerce an approved drug that is the subject of any "covered application," as defined in Section 505-
l(b)(2), if a REMS is required with respect to the drug and the person or entity fails to maintain
compliance with the requirements of the approved REMS or other requirements under Section 505-1 of
the FD&C Act. Id. §§ 355(p)(1), 355-1(b)(2); see also infra notes 14-16 (discussing the covered
applications, which include an NDA, ANDA, and BLA). A violation of Section 505(p) or Section 505-1
is subject to civil monetary penalties of up to $250,000 per violation, not to exceed $I million in a single
proceeding. 21 U.S.C. § 333(f)(4)(A)(i). These penalties increase if the violation continues for more
than thirty days after FDA notifies the responsible person or entity, doubling for the second thirty-day
period and continuing to double for subsequent thirty-day periods, up to $1 million per period and $10
million per proceeding. Id. § 333(f)(4)(A)(ii). In addition, under Section 502(y) of the FD&C Act, a
drug is misbranded if a responsible person or entity fails to comply with a requirement of an approved
REMS. Id. § 352(y). Misbranding may lead to both criminal and civil penalties, as well as collateral
consequences including potential debarment and exclusion from future participation in federal health
care programs. See generally id. § 333 (providing criminal and civil penalties for violations of § 331,
which addresses, inter alia, misbranding of drugs); id. § 335a (detailing debarment provisions); 42
U.S.C. § 1320a-7(a)-(b) (2006 & West Supp. 2009) (authorizing the exclusion of certain individuals and
entities from participation in federal health care programs for certain criminal convictions).
8. See infra Part I.
9. See Masoudi, supra note 5, at 586 (discussing FDA's authority under FDAAA to change the
labeling of a drug once postmarket safety information emerges).
10. See, e.g., id. at 586-87 (analyzing the FDAAA provisions relating to REMS); Jeremiah J. Kelly
& Michael David, No Longer "If" But "When ": The Coming Abbreviated Approval Pathway for
Follow-on Biologics, 64 FOOD & DRUG L.J. 115, 143-44 (2009) (arguing that REMS provisions should
be applied to new abbreviated approval pathway for follow-on biologics under the Public Health Service
Act).
11. See infra Part If.
12. See infra Part lI.A.
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particular, the availability of a preemption defense in the wake of the Supreme




Pursuant to its new REMS authority, FDA may require an NDA,14 ANDA,' s
or BLA 16 applicant to submit a proposed REMS as part of its initial application if,
after considering certain factors, the agency "determines that a [REMS] is
necessary to ensure that the benefits of the drug outweigh the risks of the drug
...... 17 FDA also may require the sponsor of an approved NDA, ANDA, or BLA to
implement a REMS if the agency "becomes aware of new safety information and
makes a determination that such a strategy is necessary to ensure that the benefits
of the drug outweigh the risks of the drug.'
8
The only element required for all REMS is a timetable for assessing the
REMS' effectiveness; sponsors generally must conduct three such assessments
during the seven years following the REMS' approval. 19 In addition, however, FDA
may-and as a general matter, does-require additional REMS elements, which
range in complexity and in the burden they impose on manufacturers. 0 On the least
onerous end of the scale, FDA may require the sponsor to create a medication guide
13. 129 S. Ct. 1187 (2009).
14. 21 U.S.C. §§ 355(p)(1), 355-1(b)(2) (West Supp. 2009) (authorizing mandatory REMS for
drugs approved under 21 U.S.C. § 355(b) (NDAs)).
15. Id. (authorizing mandatory REMS for drugs approved under 21 U.S.C. § 3550) (ANDAs)).
16. See id. (authorizing mandatory REMS for drugs approved under 42 U.S.C. § 262 (BLAs)).
17. Id. § 355-1(a)(1). In making its determination, the agency is required to consider:
(A) The estimated size of the population likely to use the drug involved[;] (B) The
seriousness of the disease or condition that is to be treated with the drug[;] (C) The expected
benefit of the drug with respect to such disease or condition[;j (D) The expected or actual
duration of treatment with the drug[;] (E) The seriousness of any known or potential adverse
events that may be related to the drug and the background incidence of such events in the
population likely to use the drug[; and] (F) Whether the drug is a new molecular entity.
Id.
18. Id. § 355-1(a)(2)(A).
19. Id. § 355-1(c)-(d). Sponsors generally are required to conduct assessments within eighteen
months after the REMS' approval, within three years after the approval, and within the seventh year
after the approval. Id.; see also Masoudi, supra note 5, at 587 (noting that all REMS must include a
timetable for assessing the plan's performance, and that this is the only required element).
20. See 21 U.S.C. § 355-1(e)-(f) (providing FDA with the discretionary authority to require
additional elements in an REMS, including medication guides, communication plans, and elements to
assure safe use); Barbara J. Evans, Seven Pillars of a New Evidentiary Paradigm: The Food, Drug, and
Cosmetic Act Enters the Genomic Era, 85 NOTRE DAME L. REV. 419, 512 (2010) (noting that some of
the additional REMS elements are "simple, familiar measures FDA already has been using," but that
others are "more draconian").
2010]
JOURNAL OF HEALTH CARE LAW & POLICY
pursuant to 21 C.F.R. Part 208. In the middle of the scale, FDA may mandate
other communication elements, such a patient package insert or letters to health
care providers. 22 At the more onerous end of the scale are so-called elements to
assure safe use (ETASU). 23 These can include: training or certification for those
who prescribe or dispense the drug, limiting the settings in which the drug can be
dispensed, requiring patients to provide documentation of laboratory test results, or
requiring registration or monitoring of patients using the drug.24
B. Implementation of REMS
FDA approved the first new REMS 25-for Treximet (sumatriptan succinate
and naproxen sodium) Tablets--on April 15, 2008.26 Since then, FDA has
21. 21 U.S.C. § 355-1(e)(2)(A); 21 C.F.R § 208.20 (2009). Medication guides are paper handouts
that are provided with prescription medications. U.S. Food & Drug Admin., Medication Guides,
http://www.fda.gov/Drugs/DrugSafety/ucmO85729.htm (last visited May 17, 2010). "The guides address
issues.., specific to particular drugs and drug classes, and they contain FDA-approved information...
[designed] to help patients avoid serious adverse events." Id.
22. 21 U.S.C. § 355-1(e)(2)(B).
23. Id. § 355-1(f)(3).
24. Id. FDA may impose ETASU for a new drug where the agency determines that the drug (1) has
been shown to be effective, but (2) is associated with a "serious adverse drug experience," and (3) "can
be approved only if ... such elements are required . . . to mitigate a specific serious risk listed in the
[drug] labeling . I..." Id. § 355-1(f)(l)(A). For an approved drug, the agency must find that the drug
would be withdrawn unless ETASU are imposed and that other REMS elements are not sufficient to
mitigate the serious risk at issue. Id. ETASU must "be commensurate with the specific serious risk listed
in the labeling of the drug," must "not be unduly burdensome on patient access to the drug," and must,
"to the extent practicable,... minimize the burden on the health care delivery system ..... Id. § 355-
l (f)(2)(A), (C-(D).
On December 22, 2009, Kaiser Permanente (Kaiser), the largest private integrated health care
delivery system in the United States, submitted a citizen petition to the FDA under 21 C.F.R. § 10.30
requesting that the agency revise its standards for the development, implementation, and evaluation of
REMS. Citizen Petition of Benjamin Chu et al., Kaiser Permanente, FDA Dkt. No. FDA-2009-P-0602
(Dec. 22, 2009), available at http://www.regulations.gov/search/Regs/contentStreamer?objectld =
0900006480a71ffa&disposition=attachment&contentType=pdf [hereinafter Citizen Petition of Chu et
al.]. Kaiser's Citizen Petition focuses in large part on ETASU, and requests that the agency: (1)
"[i]ncrease the transparency and opportunity for comment by health care providers and ... the public in
the development process for REMS" involving ETASU; (2) make summary data collected as a result of
REMS publicly available; (3) evaluate ETASU regularly to assess their effectiveness and include health
care providers in that process; (4) ensure REMS are not used by drug companies to give preference to
particular health care providers such as specialty pharmacies; and (5) take steps to guard the
confidentiality of Protected Health Information disclosed as a result of REMS. Id. at 1-2.
25. Drugs approved before FDAAA's effective date were deemed to have an approved REMS in
effect if certain conditions were met. See Identification of Drug and Biological Products Deemed to
Have Risk Evaluation and Mitigation Strategies for Purposes of the Food and Drug Administration
Amendments Act of 2007, 73 Fed. Reg. 16,313, 16,313 (Mar. 27, 2008) (indicating that certain drugs
approved prior to FDAAA, which were effectively subject to ETASU, were deemed to have a REMS,
requiring manufacturers to submit a proposed REMS to FDA). On March 27, 2008, the FDA published a
Notice identifying sixteen drug and biological products deemed to have a REMS. Id. at 16,314 tbl.l.
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27
approved REMS for a wide range of drugs across a variety of therapeutic areas.
Indeed, the agency required a REMS for one-third of new molecular entities
approved in the first six months of its REMS authority.28 Moreover, the agency
appears to have approved REMS at an increasing pace: it approved twenty-five new
REMS or modifications between April and December 2008, and more than triple
that number-seventy-four-between January and December 8, 2009.29 While it is
unclear whether Congress intended REMS to be required sparingly, it appears that
FDA views REMS as a powerful tool to help the agency better understand a
product's use in the marketplace and is imposing REMS liberally as a result.
Of the REMS and modifications approved to date, the vast majority-eighty-
four-include only a medication guide. 30  Twenty-four also include a
communication plan,3' while thirteen involve ETASU and/or an implementation
system.32 In addition, while FDA initially only approved REMS that were specific
to an individual drug or biologic,33 the agency more recently has required REMS
for classes of drug products.34 The agency has implemented class-wide REMS for
botulinum toxin-based products, testosterone gel products, and erythropoiesis-
26. See U.S. Food & Drug Admin., Approved Risk Evaluation and Mitigation Strategies (REMS),
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatientsandProviders/ucm I
11350.htm (last visited May 17, 2010) (providing a list of approved REMS).
27. See id. (listing the numerous drugs with FDA-approved REMS); Evans, supra note 20, at 514
(discussing the various drugs subject to REMS, including those with abuse or addiction potential, or
drugs with grave use-risks, such as birth defects or irreversible organ damage).
28. Lauren Smith, The REMS Report Card: FDA Using New Tools for One-Third of New Drugs in
First Six Months, THE PINK SHEET, Nov. 10, 2008.
29. U.S. Food & Drug Admin., supra note 26. Between January and April 2010, FDA has approved
twenty-two new REMS. Id.
30. Id.
31. 1d.
32. Id. As of May 17, 2010, FDA's list of approved REMS includes 121 separate products and
identifies the elements associated with each REMS. Id. The approval dates included in the list, however,
indicate that the agency has approved a total of 154 new REMS and/or modifications to existing REMS.
Id.
33. See Evans, supra note 20, at 513-15 (discussing the initial REMS approvals granted by the
FDA and indicating that the specific drug and biologic products were approved on a case-by-case basis).
34. See Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public
Meeting, 74 Fed. Reg. 17,967, 17,969 (Apr. 20, 2009) (providing notice of a public meeting to discuss
the development of REMS for classes of certain opioid drugs); CTR. FOR LAWFUL ACCESS & ABUSE
DETERRENCE, A REVIEW OF THE FDA'S APPROACH TO IMPLEMENTING A CLASS-WIDE REMS FOR
LONG-ACTING AND EXTENDED-RELEASE OPIOIDS 1, 3-4 (2010), available at
http://claad.org/downloads/REMS%20-%20FDA%2OApproach%2OCritique%2OFinal.pdf (noting that
the FDA has exercised its new authority to require certain producer of opioid drugs to propose a "class-
wide, one-size-fits-all REMS," and suggesting that the April 2009 meeting called by the FDA to discuss
these proposals indicates that the FDA has "erroneously invoked the provisions Congress intended to
guide assessments of individual drugs' existing REMS"); Ravi Deshpande, REMS Programs: Five
Trends to Watch, REG. POL'Y MARKET ACCESS REP., Aug. 2009, at 1, 2, available at
http://www.mckesson.com/static-files/McKesson.com/McKSpecialty/PDFs/REMS0908rpm-SiteLicens
e.pdf (discussing the arguments for and against class-wide REMS).
2010]
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stimulating agents,35 and is in the process of developing a class-wide REMS for
extended-release oral opioid drug products.36
C. Draft REMS Guidance
In September 2009, FDA issued a Draft Guidance for Industry entitled
"Format and Content of Proposed Risk Evaluation and Mitigation Strategies
(REMS), REMS Assessments, and Proposed REMS Modifications" (Draft REMS
Guidance).37 The Draft REMS Guidance addresses the format and content of the
proposed REMS and REMS supporting document,38 and requires copies of all
documents relevant to REMS elements (such as medication guides and patient
package inserts) to be appended to the proposed REMS. 39 The Draft REMS
Guidance also offers detailed instructions on submitting modifications to approved
REMS and explicitly requires that:
Any proposed modification to [an] approved REMS, including any
proposed changes to materials that are included as part of the REMS
(e.g., communication and education materials, enrollment forms,
prescriber and patient agreements), must be submitted as a proposed
modification to an approved REMS in a new prior-approval
35. Press Release, U.S. Food & Drug Admin., FDA Announces New Safety Plan for Agents Used
to Treat Chemotherapy-Related Anemia (Feb. 16, 2010), available at http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm200471.htm; Press Release, U.S. Food & Drug Admin.,
Testosterone Gel Safety Concerns Prompt FDA to Require Label Changes, Medication Guide (May 7,
2009), available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucml49580.htm;
Press Release, U.S. Food & Drug Admin., FDA Requires Boxed Warning for All Botulinum Toxin
Products (Apr. 30, 2009), available at http://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/ucm I49574.htm.
36. The agency has held a series of public and private meetings related to this proposed REMS. See
Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public Meeting, 74 Fed.
Reg. at 17,968-69 (discussing efforts to address the risks of opioid use via REMS); Press Release, U.S.
Food & Drug Admin., Opioid Drugs and Risk Evaluation and Mitigation Strategies (REMS), available
at http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucml63647.htm (last visited May
17, 2010) (documenting the various meetings to discuss the use of REMS for opioids). As noted in
Kaiser's Citizen Petition, although Section 505-1 of the FD&C Act requires FDA to obtain "input from
patients, physicians, pharmacists and other health care providers about how the elements to assure safe
use.., for 1 or more drugs may be standardized so as not to be... unduly burdensome on patient access
to the drug," the proposed opioid REMS is the first for which the agency has sought public input. See
Citizen Petition of Chu et al., supra note 24, at 3.
37. U.S. FOOD & DRUG ADMIN., U.S. DEP'T OF HEALTH & HUMAN SERVS., GUIDANCE FOR
INDUSTRY: FORMAT AND CONTENT OF PROPOSED RISK EVALUATION AND MITIGATION STRATEGIES
(REMS), REMS ASSESSMENTS, AND PROPOSED REMS MODIFICATIONS DRAFT GUIDANCE (2009),
available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/
Guidances/UCM 184128.pdf thereinafter DRAFT REMS GUIDANCE].
38. Id. at 1. According to FDA, the proposed REMS is "a concise document that describes the
proposed goals and elements of the REMS" while the REMS supporting document "expands on
information included in the proposed REMS and provides additional information not included in the
proposed REMS .... " Id. at 7.
39. Id. at 8, 10.
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supplemental application... and must not be implemented until the
modified REMS is approved by FDA.4 °
II. DISCUSSION
A REMS does not spring into existence. Rather, when FDA orders a sponsor
to propose a REMS, the company faces a number of significant challenges in
developing it, getting FDA approval, putting the REMS into practice and
maintaining it. In addition to these challenges, however, the REMS process offers
drug manufacturers substantial opportunities, which should not be-and have not
been-overlooked. Moreover, the REMS process may give rise to specific
challenges and opportunities with respect to potential state tort litigation. Perhaps
most notably, it is possible that a REMS will serve to preempt certain state tort law
failure-to-warn claims, although the likelihood and scope of such preemption is
unclear in light of the Supreme Court's recent decision in Wyeth. The discussion
below first addresses certain challenges and opportunities specific to tort
litigation, 4' before turning to some of the more general challenges and opportunities
that companies may encounter while operating under a REMS.42
A. Tort Liability
1. Preemption
A potential benefit for manufacturers with a product subject to a REMS is that
actions taken under the REMS, which require prior approval by FDA,43 may
preempt state law failure-to-warn claims. In 2006, the FDA issued a rule regarding
the requirements for human prescription drug and biologics labeling, the Preamble
to which clearly expressed the agency's view that FDA labeling approval
preempted conflicting or contrary state law.an In particular, the agency warned that
state tort actions "encourage, and in fact require, lay judges and juries to second-
guess the assessment of benefits versus risks of a specific drug to the general
public-the central role of FDA," and could "pressure... manufacturers.., to add
40. Id. at 22.
41. See infra Part II.A.
42. See infra Parts Il.B-C.
43. See supra Part I.A.
44. Requirements on Content and Format of Labeling for Human Prescription Drug and Biological
Products, 71 Fed. Reg. 3922, 3922, 3934 (Jan. 24, 2006) (effective date June 30, 2006) [hereinafter FDA
Preamble]; Victor E. Schwartz et al., Marketing Pharmaceutical Products in the Twenty-First Century:
An Analysis of the Continued Viability of Traditional Principles of Law in the Age of Direct-to-
Consumer Advertising, 32 HARv. J.L. & PUB. POL'Y 333, 380 (2009). The FDA Preamble stressed that
"FDA is the expert Federal public health agency charged by Congress with ensuring that drugs are safe
and effective, and that their labeling adequately informs users of the risks and benefits of the product
and is truthful and not misleading." FDA Preamble, supra, at 3934.
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warnings that FDA has neither approved nor found to be scientifically required. ' 5
Although the agency acknowledged that its regulation of drug labeling would not
preempt all state tort actions, 46 FDA identified six types of claims that it believed
would be preempted by its regulation of prescription drug labeling.47
The Supreme Court specifically considered the FDA Preamble in Wyeth, en
route to concluding that Wyeth had not demonstrated a sufficient conflict between
state and federal regulation to establish a preemption defense against a state tort
law failure-to-warn claim.4 8 Diana Levine, the Wyeth plaintiff, received an
incorrect IV-push administration of an anti-nausea drug manufactured by Wyeth,
which caused gangrene and the eventual amputation of her forearm. 49 "Although
[the drug]'s labeling warned of the danger of gangrene and amputation following
inadvertent intra-arterial injection, Levine [nevertheless] alleged that the labeling
was defective because it failed to instruct clinicians to use the IV-drip method of
intravenous administration instead of the higher risk IV-push method." 50 Levine
was awarded a $7.4 million jury verdict, which the trial court refused to overturn
on preemption grounds, and which the Vermont Supreme Court affirmed.5 1
The Supreme Court's opinion in Wyeth rejected two preemption arguments
advanced by Wyeth: first, "that it would have been impossible for [the company] to
comply with the state-law duty to modify [the drug]'s labeling without violating
federal law," and second, "that requiring [the company] to comply with a state-law
duty to provide a stronger warning about IV-push administration would obstruct the
purposes and objectives of federal drug labeling regulation. 52 As to the first
argument, the Court found that, while manufacturers generally are required to
obtain FDA approval of a supplemental application before changing a drug label,
FDA's "changes being effected" (CBE) regulation permits a manufacturer to "add
or strengthen a contraindication, warning, precaution, or adverse reaction" or "an
instruction about dosage and administration that is intended to increase the safe use
of the drug product ...upon filing its supplemental application with the FDA
.... ,53 As to those categories of information, a manufacturer "need not wait for
FDA approval" before changing a drug label, and the Court therefore concluded
45. FDA Preamble, supra note 44, at 3935.
46. Id. at 3936.
47. Id. at 3935-36. In particular, the agency acknowledged that "[tihe Supreme Court has held that
certain State law requirements that parallel FDA requirements may not be preempted." Id. at 3936
(citing Medtronic, Inc. v. Lohr, 518 U.S. 470, 495 (1996)).
48. See 129 S. Ct. 1187, 1200-02, 1204 (2009) (noting that the FDA Preamble "is at odds with...
Congress' purposes, and it reverses the FDA's own longstanding position without providing a
reasonable explanation").
49. Id. at 1191.
50. Id. at 1191-92.
51. Id. at 1193.
52. Id. at 1193, 1199.
53. Id. at 1196 (quoting 21 C.F.R. §§ 314.70(c)(6)(iii)(A), (C)) (internal quotations omitted).
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that Wyeth would, at least in theory, have been permitted to strengthen its label to
warn about the dangers of IV-push administration. 54 The Court further found that
Wyeth had not provided "clear evidence that the FDA would not have approved a
change to the ... label" and therefore had not demonstrated "that it was impossible
... to comply with both federal and state requirements." 55
Wyeth's second preemption argument-that recognizing Levine's state tort
action would interfere with federal regulation of drug labeling-relied in part upon
the FDA Preamble.56 In addressing Wyeth's second argument, the Court first
observed:
If Congress thought state-law suits posed an obstacle to its objectives, it
surely would have enacted an express preemption provision at some
point during the [FD&C Act]'s 70-year history. But despite its 1976
enactment of an express pre-emption provision for medical devices,
Congress has not enacted such a provision for prescription drugs.
57
The Court then turned to the FDA Preamble, and in particular, its position that the
FD&C Act establishes "both a 'floor' and a 'ceiling"' that prevents manufacturers
from including unsubstantiated risk information on drug labels.58 The Court found
the FDA Preamble did not merit deference because it "relie[d] on an untenable
interpretation of congressional intent and an overbroad view of an agency's power
to pre-empt state law." 59 Specifically, the Court observed that because "FDA long
maintained that state law offers an additional, and important, layer of consumer
protection that complements FDA regulation[, t]he agency's 2006 preamble
represents a dramatic change in position.,
60
While Wyeth concluded that FDA regulation did not preempt a state tort law
failure-to-warn claim, it did so in the very specific context of, and relied heavily
upon, the CBE regulation. 6 1 In stark contrast to the CBE regulation, however, the
FDA's recent Draft REMS Guidance makes clear that (1) any proposed
modification to an approved REMS-or the tools implementing it-"must be
submitted... in a new prior-approval supplemental application," and (2) proposed
modifications "must not be implemented until the modified REMS is approved by
FDA., 62 These key distinctions may well prove significant to the potential viability
of a preemption defense based on a REMS because, unlike in Wyeth, a drug
manufacturer operating under a REMS cannot add additional warnings to its REMS
54. Id.
55. Id. at 1198-99.
56. Id. at 1200-01.
57. Id. at 1200 (citation omitted).
58. Id. (quoting FDA Preamble, supra note 44, at 3935).
59. Id. at 1199.
60. Id. at 1202-03.
61. Id. at 1199, 1204.
62. DRAFT REMS GUIDANCE, supra note 37, at 22.
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materials without explicit pre-approval by FDA. Rather, a manufacturer may be
able to successfully defend against a state tort failure-to-warn claim based upon a
REMS by arguing that it is impossible to comply with both FDA's interpretation of
its REMS authority and state law duties that would require additional warnings.
6 3
For the same reason, a preemption defense may be available where a drug label
specifically refers to REMS materials for their discussion of a specific risk.64
In many respects, a preemption defense premised on the presence of a REMS
is perfectly intuitive. Notably, FDA may require a REMS where it concludes that
one "is necessary to ensure that the benefits of the drug outweigh the risks of the
drug" after considering certain factors. 65 FDA then requires the drug sponsor to
propose a REMS and all of the implementing tools (e.g., communication materials),
works with the sponsor to ensure that the REMS properly describes the risk at issue
and provides appropriate safety information, and eventually approves the REMS.
66
Through these processes, FDA squarely focuses on the risk in question and strikes
what it considers to be an appropriate balance with respect to risk information. So
too, the REMS process is likely to generate a substantial administrative record
demonstrating FDA's consideration of the specific risk and, perhaps, the agency's
rationale in approving the ultimate balance reflected in the REMS. A lack of this
type of agency focus-and corresponding administrative record-was one of the
very factors the Court found weighed against preemption in Wyeth.67 As such,
evidence of agency focus, demonstrated through an administrative record, may
bolster the argument for preemption based upon a REMS.
2. Litigation Risks and Strategy
Aside from the open question of whether a REMS may give rise to a
preemption defense against state tort law failure-to-warn claims, REMS may create
additional challenges and opportunities for manufacturers with respect to tort
liability. Most obviously, a REMS is likely to lead to increased visibility regarding
63. Cf Wyeth, 129 S. Ct. at 1198-99 (implying that had the company not been able to comply with
both laws the state claim would have been preempted).
64. Indeed, given the opposing requirements of the CBE regulation and Draft REMS Guidance, a
manufacturer may find itself in the position of adding risk information to its label that it may not include
in its REMS because it has not yet been approved by FDA. This would certainly be ironic since the
REMS is supposed to serve as the primary mechanism for communicating risk information.
65. 21 U.S.C. § 355-1 (a)(l) (West Supp. 2009); see supra note 17.
66. § 355-1(a)(1), (h)(l).
67. See Wyeth, 129 S.Ct. at 1198-99 ("[W]hile [Wyeth] does suggest that the FDA intended to
prohibit it from strengthening the warning about IV-push administration because the agency deemed
such a warning inappropriate in reviewing [the drug]'s . . . applications, both the trial court and the
Vermont Supreme Court rejected this account as a matter of fact. In its decision on Wyeth's motion for
judgment as a matter of law, the trial court found 'no evidence in th[e] record that either the FDA or the
manufacturer gave more than passing attention to the issue of' IV-push versus IV-drip administration.").
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a drug's safety profile.68 Although all drugs have inherent safety risks, and FDA
can only approve a REMS "to ensure that the benefits ... outweigh the risks" of an
otherwise safe and effective drug,69 a REMS essentially spotlights safety issues for
potential plaintiffs. Such a spotlight may be particularly damaging if only one drug
in a class is subject to a REMS, insofar as plaintiffs may argue that they would
have used alternative therapies if the drug's REMS had provided other risk
information. Moreover, the REMS process-which, as discussed above, may lead
to the creation of an administrative record useful for preemption purposes-also
may lead to the creation of documents that highlight the risks at issue or could
otherwise be used to cast a manufacturer in a negative light during litigation.
On the other hand, a REMS may play a key role in a drug manufacturer's
efforts to avoid tort litigation altogether, or may better position a manufacturer in
event of litigation. As discussed below, a REMS may offer a manufacturer
increased opportunities to communicate important safety information to health care
providers and patients before a drug is used.7° In this way, a REMS may ensure
safe use in the first instance, such as by requiring laboratory testing for key risk
factors, and thereby avoid future tort claims.71 The REMS process also may afford
a manufacturer the chance to demonstrate its commitment to working cooperatively
with FDA. Thus, documents created during the REMS process may portray the
manufacturer in a positive light and may be helpful in defending against tort
litigation. And, in the most dramatic instance, a REMS may constitute a strong
defense against a state tort law failure-to-warn claim because it is specifically
designed-and approved by FDA-to provide appropriate risk information to
relevant health care provider and patient populations.
B. Challenges
In addition to raising specific issues with respect to tort liability, REMS and
the REMS development, implementation, and maintenance processes present a host
of other challenges and opportunities, which manufacturers and FDA are only
beginning to navigate. Perhaps most obviously, the process of proposing and
implementing a REMS can involve substantial costs, financial and otherwise. For
instance, the financial costs involved in designing and implementing a REMS may
68. See § 355-1(h)(3)(C) (requiring that action letters and orders addressing risk evaluation and
management strategies be publicly available); Masoudi, supra note 5, at 587 (noting that FDA can
require dissemination of communications including certain REMS protocols).
69. § 355-1(a)(1).
70. See infra Part II.C.
71. See Christof A. Marr & Peggy Berry, Designing a Safety Risk Management Strategy, REG.
Focus, Nov. 2008, at 20, 21-25 (discussing how REMS impact the medical industry's role in providing
a higher level of care to patients); Eli Lilly & Co., Risk Evaluation and Mitigation Strategies (REMS):
What Does a REMS Look Like?, http://safetymatters.lilly.com/rolelilly/riskEvalMitigationPlan.htm (last
visited May 17, 2010) (stating that some REMS require special procedures, such as mandatory
laboratory tests, to be administered before a REMS product is issued to a patient).
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include preparing communication tools such as Dear Health Care Provider Letters,
establishing training and certification systems, creating monitoring and registry
systems, and designing limited dispensing procedures.72 While these costs are
unlikely to be entirely avoidable, a sponsor may be able to minimize some of them
if it can anticipate that FDA may require a REMS for its drug, perhaps because
REMS have been required for other drugs in a class. Such anticipation may allow a
sponsor to handle projects internally that would otherwise need to be outsourced,
and also may allow a company to avoid an otherwise likely delay in product
launch.
Once a REMS is designed, proposed, and approved, the sponsor faces
additional financial costs in maintaining the REMS, such as performing the
assessments required by the REMS statute. 3 Sponsors also may propose
modifications to an approved REMS at any time74 and, as the Draft REMS
Guidance makes clear, any proposed modification to a REMS--or the tools
implementing the approved REMS-must be submitted in a new prior-approval
supplemental application. 7 5 Given their respective complexities, preparing REMS
assessments and REMS supplemental applications both are likely to involve
substantial financial costs for REMS sponsors.
In addition to financial costs, operating under a REMS may impose certain
commercial costs on a manufacturer as well. As a fundamental matter, a highly
restrictive REMS, such as one that limits the settings in which a drug may be
dispensed, may impact significantly the volume of a drug that can be distributed.
Such limitations on availability may make health care providers less likely to
prescribe a particular drug, especially if an equally effective alternative therapy is
available.76 Health care providers also may be more reluctant to prescribe or
72. See Alan Minsk & Lanchi Nguyen, REMS, Risk and Reward, LJN's PROD. LIAB. L. &
STRATEGY NEWSLETTER (Incisive Media, New York, N.Y.), Oct. 2009, at 7, 7 (discussing the benefits
and risks of REMS implementation).
73. As noted above, sponsors are generally required to assess a REMS' effectiveness three times
within the seven years after its approval. See supra note 19. Sponsors also may voluntarily submit
assessments at any time, and are required to submit an assessment 1) when submitting a supplemental
application for a new indication for use, 2) when required by FDA if the agency determines that new
safety or effectiveness information indicates that an element should be modified or included in the
REMS, and 3) within fifteen days when ordered by FDA if the agency determines there may be cause
for withdrawal or suspension of approval under Section 505(e) of the FD&C Act. DRAFT REMS
GUIDANCE, supra note 37, at 6-7.
74. § 355-1(g)( 4 ).
75. Per the Draft REMS Guidance, this supplemental application must include: (i) a new proposed
REMS showing the complete previously approved REMS and highlighting the proposed modifications,
and (ii) "an update to the REMS supporting document that includes the rationale for and description of
all proposed modifications and any impact the proposed modifications would have on other REMS
elements." DRAFT REMS GUIDANCE, supra note 37, at 22.
76. See Citizen Petition of Chu et al., supra note 24, at 7 ("In effect, [ETASU] create[ ] a separate
category of drugs, which require considerably more labor in the health care delivery setting to satisfy
REMS ETASU requirements and to provide the drug in the safest manner possible.").
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dispense a certain drug if the REMS' ETASU require action-such as certification
or training-on the part of such providers or require providers to engage in specific
patient education prior to use.77 In essence, any REMS element that requires
additional effort on the part of health care providers is likely to adversely impact
sales, at least where an alternative therapy is available.
A REMS that relates to a specific drug (as opposed to a class-wide REMS)
also may involve notable competitive costs for the drug at issue. Even though FDA
can only impose REMS on drugs and biologics that the agency otherwise finds to
be safe and effective, the existence of a REMS may give health care providers or
patients the impression that a specific drug or biologic presents higher safety risks
than alternative therapies.78 The drug with the REMS may suffer competitively,
particularly where only one drug in a class has a REMS, or where a new drug with
a REMS enters the market against already approved drugs that have similar risks
but no REMS. Drug manufacturers are, of course, most interested in ensuring that
important risk information about their products is communicated to appropriate
patients in an effective manner. 79 Nevertheless, these significant financial,
commercial, and competitive costs cannot be ignored by manufacturers.
Moreover, in addition to costs, a REMS involves a heightened level of
complexity for a manufacturer. Even without a REMS in place, companies face
significant administrative burdens in ensuring that drug labels reflect appropriate
and up-to-date risk information, as required by the FD&C Act and FDA's
implementing regulations. Maintaining a REMS likely will add another layer of
complexity to such companies' operations, which in turn will increase the costs of
compliance.
C. Opportunities
While operating under a REMS involves obvious burdens, there also seem to
be a number of potential opportunities presented by the REMS process. For
instance, the REMS proposal and approval process requires drug sponsors to focus
on their product's risk profile earlier, with greater intensity and frequency.8° While
77. See Citizen Petition of Chu et al., supra note 24, at 4 ("REMS with ETASU can substantially
increase the workload burden and costs associated with the prescribing, dispensing, administration and
management of certain drugs .... ); Minsk & Nguyen, supra note 72, at 11 ("[M]echanisms required to
ensure the safe use of the product can ... [cause] a physician's reluctance to prescribe with restrictions
or additional responsibilities.").
78. Minsk & Nguyen, supra note 72, at 11.
79. Cf PHARM. RESEARCH & MFRS. OF AM., PHRMA GUIDING PRINCIPLES: DIRECT TO
CONSUMERS ADVERTISEMENTS ABOUT PRESCRIPTION MEDICINES 3 (2008),
http://www.phrma.org/files/attachments/PhRMA%2OGuiding%2OPrinciplesDec %28-FINAL.pdf
("[Direct-to-consumer] communications ... can be a powerful tool for reaching and educating millions
of people, and [pharmaceutical manufacturers] are committed to ensuring that . . . [such]
communications provide accurate, accessible and useful health information to patients and consumers.").
80. Minsk & Nguyen, supra note 72, at 12.
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this may appear to be a cost, it can in fact be an opportunity insofar as it gives a
manufacturer some chance to minimize the risks involved in using its drug by
providing accurate and effective information to health care providers and patients.8'
Indeed, in certain instances where a significant risk exists, a REMS may offer the
only means of providing patients with access to a drug, for instance through a
82restricted distribution system.
Moreover, a REMS that involves a communication plan creates notable
opportunities to the extent that it affords a drug sponsor additional avenues through
which to communicate with health care providers regarding a particular product. In
addition to disseminating safety information through these channels, the sponsor
may be able to garner important information about how the drug is used in practice,
which may in turn inform the safety information the company seeks to disseminate.
Of course, however, the restrictions that generally apply to manufacturers'
communications with health care providers-such as the prohibition on off-label
promotion by manufacturers83 -continue to apply in the context of REMS-
mandated communications.
Finally, in addition to increased opportunities to communicate with health
care providers and patients, the REMS approval process may provide sponsors with
the chance for additional pre-approval interaction with the FDA. Ideally, this
interaction would allow sponsors to gain increased understanding of FDA's views
on the drug or biologic at issue, and might even lead to faster approvals.
CONCLUSION
In summary, while it remains to be seen what impact REMS will have on
manufacturer tort liability, and while it is clear that developing, implementing, and
maintaining a REMS will involve significant burdens for manufacturers, the
81. Id.
82. See Citizen Petition of Chu et al., supra note 24, at 7 ("By design, [S]ection 505-1(f) [of the
FD&C Act] makes some drugs available that would otherwise not be dispensed outside of an
investigational setting, expanding treatment options for patients.").
83. See Wash. Legal Found. v. Henney, 202 F.3d 331, 332-33 (D.C. Cir. 2000) ("[l~t is unlawful
for a manufacturer to introduce a drug into interstate commerce with an intent that it be used for an off-
label purpose, and a manufacturer illegally 'misbrands' a drug if the drug's labeling includes
information about its unapproved uses." (citing 21 U.S.C. §§ 33 1(a), (d), 352(a)) (citations omitted)). By
regulation, FDA has broadly defined labeling to include:
Brochures, booklets, mailing pieces, detailing pieces, file cards, bulletins, calendars, price
lists, catalogs, house organs, letters, motion picture films, film strips, lantern slides, sound
recordings, exhibits, literature, and reprints and similar pieces of printed, audio, or visual
matter descriptive of a drug and references published (for example, the "Physicians Desk
Reference") for use by medical practitioners, pharmacists, or nurses, containing drug
information supplied by the manufacturer, packer, or distributor of the drug and which are
disseminated by or on behalf of its manufacturer, packer, or distributor ....
21 C.F.R. § 202.1()(2).
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possibility also exists that FDA's new authority will, at least in some ways, prove
beneficial for drug manufacturers.

